4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
Public ClinicalTrials.gov record NCT01587898. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Four-week Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a four-week Phase IIa, randomized, double-blind, placebo-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in approximately 68 subjects with anemia associated with chronic kidney disease who are not taking rhEPO and are not undergoing dialysis. The range of Hgb values for study eligibility is 8.5-11.0 g/dL. Eligible subjects will be randomized in equal proportions to receive once daily (QD) placebo or GSK1278863 0.5 mg, 2 mg or 5 mg in a double-blind fashion.
Study identification
- NCT ID
- NCT01587898
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 72 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 16, 2012
- Primary completion
- May 6, 2013
- Completion
- May 6, 2013
- Last update posted
- Nov 8, 2017
2012 – 2013
United States locations
- U.S. sites
- 46
- U.S. states
- 13
- U.S. cities
- 41
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Azusa | California | 91702 | — |
| GSK Investigational Site | Bakersfield | California | 93309 | — |
| GSK Investigational Site | Chino | California | 91710 | — |
| GSK Investigational Site | Los Angeles | California | 90022 | — |
| GSK Investigational Site | Los Angeles | California | 90025 | — |
| GSK Investigational Site | Los Angeles | California | 90057 | — |
| GSK Investigational Site | North Hollywood | California | 91606-1559 | — |
| GSK Investigational Site | Orange | California | 92868 | — |
| GSK Investigational Site | Riverside | California | 92505 | — |
| GSK Investigational Site | San Dimas | California | 91773 | — |
| GSK Investigational Site | West Hills | California | 91307 | — |
| GSK Investigational Site | Yuba City | California | — | — |
| GSK Investigational Site | Denver | Colorado | 80230 | — |
| GSK Investigational Site | Daytona Beach | Florida | 32117 | — |
| GSK Investigational Site | Edgewater | Florida | 32132 | — |
| GSK Investigational Site | Fort Lauderdale | Florida | 33308 | — |
| GSK Investigational Site | Jacksonville | Florida | 32258 | — |
| GSK Investigational Site | Miami | Florida | 33145 | — |
| GSK Investigational Site | Miami | Florida | 33150 | — |
| GSK Investigational Site | Miami | Florida | 33173 | — |
| GSK Investigational Site | Ocala | Florida | 34471 | — |
| GSK Investigational Site | Pembroke Pines | Florida | 33028 | — |
| GSK Investigational Site | Port Charlotte | Florida | 33952 | — |
| GSK Investigational Site | Savannah | Georgia | 31406 | — |
| GSK Investigational Site | Evanston | Illinois | 60201 | — |
| GSK Investigational Site | Gurnee | Illinois | 60031 | — |
| GSK Investigational Site | Detroit | Michigan | 48236 | — |
| GSK Investigational Site | Asheville | North Carolina | 28801 | — |
| GSK Investigational Site | Charlotte | North Carolina | — | — |
| GSK Investigational Site | Wilmington | North Carolina | 28401 | — |
| GSK Investigational Site | Winston-Salem | North Carolina | 27103 | — |
| GSK Investigational Site | Columbus | Ohio | 43210 | — |
| GSK Investigational Site | Oklahoma City | Oklahoma | 73116 | — |
| GSK Investigational Site | Portland | Oregon | 97210 | — |
| GSK Investigational Site | Bethlehem | Pennsylvania | 18017 | — |
| GSK Investigational Site | Erie | Pennsylvania | 16507 | — |
| GSK Investigational Site | Uniontown | Pennsylvania | 15401 | — |
| GSK Investigational Site | Arlington | Texas | 76011 | — |
| GSK Investigational Site | Austin | Texas | 78751 | — |
| GSK Investigational Site | Corsicana | Texas | 75110 | — |
| GSK Investigational Site | Greenville | Texas | 75402 | — |
| GSK Investigational Site | Houston | Texas | 77054 | — |
| GSK Investigational Site | Houston | Texas | 77099 | — |
| GSK Investigational Site | San Antonio | Texas | 78229 | — |
| GSK Investigational Site | Temple | Texas | 76502 | — |
| GSK Investigational Site | Silverdale | Washington | 98383 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01587898, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 8, 2017 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01587898 live on ClinicalTrials.gov.